PURPOSE: Previous studies have suggested that higher plasma 25-hydroxyvitamin D(3) [25(OH)D] levels are associated with decreased colorectal cancer risk and improved survival, but the prevalence of vitamin D deficiency in advanced colorectal cancer and its influence on outcomes are unknown. PATIENTS AND METHODS: We prospectively measured plasma 25(OH)D levels in 515 patients with stage IV colorectal cancer participating in a randomized trial ofchemotherapy. Vitamin D deficiency was defined as 25(OH)D lower than 20 ng/mL, insufficiency as 20 to 29 ng/mL, and sufficiency as ≥ 30 ng/mL. We examined the association between baseline 25(OH)D level and selected patient characteristics. Cox proportional hazards models were used to calculate hazard ratios (HR) for death, disease progression, and tumor response, adjusted for prognostic factors. RESULTS: Among 515 eligible patients, 50% of the study population was vitamin D deficient, and 82% were vitamin D insufficient. Plasma 25(OH)D levels were lower in black patients compared to white patients and patients of other race (median, 10.7 v 21.1 v 19.3 ng/mL, respectively; P < .001), and females compared to males (median, 18.3 v 21.7 ng/mL, respectively; P = .0005). Baseline plasma 25(OH)D levels were not associated with patient outcome, although given the distribution of plasma levels in this cohort, statistical power for survival analyses were limited. CONCLUSION:Vitamin D deficiency is highly prevalent among patients with stage IV colorectal cancer receiving first-line chemotherapy, particularly in black and female patients.
RCT Entities:
PURPOSE: Previous studies have suggested that higher plasma 25-hydroxyvitamin D(3) [25(OH)D] levels are associated with decreased colorectal cancer risk and improved survival, but the prevalence of vitamin Ddeficiency in advanced colorectal cancer and its influence on outcomes are unknown. PATIENTS AND METHODS: We prospectively measured plasma 25(OH)D levels in 515 patients with stage IV colorectal cancer participating in a randomized trial of chemotherapy. Vitamin D deficiency was defined as 25(OH)D lower than 20 ng/mL, insufficiency as 20 to 29 ng/mL, and sufficiency as ≥ 30 ng/mL. We examined the association between baseline 25(OH)D level and selected patient characteristics. Cox proportional hazards models were used to calculate hazard ratios (HR) for death, disease progression, and tumor response, adjusted for prognostic factors. RESULTS: Among 515 eligible patients, 50% of the study population was vitamin D deficient, and 82% were vitamin D insufficient. Plasma 25(OH)D levels were lower in black patients compared to white patients and patients of other race (median, 10.7 v 21.1 v 19.3 ng/mL, respectively; P < .001), and females compared to males (median, 18.3 v 21.7 ng/mL, respectively; P = .0005). Baseline plasma 25(OH)D levels were not associated with patient outcome, although given the distribution of plasma levels in this cohort, statistical power for survival analyses were limited. CONCLUSION:Vitamin D deficiency is highly prevalent among patients with stage IV colorectal cancer receiving first-line chemotherapy, particularly in black and female patients.
Authors: D Zehnder; R Bland; M C Williams; R W McNinch; A J Howie; P M Stewart; M Hewison Journal: J Clin Endocrinol Metab Date: 2001-02 Impact factor: 5.958
Authors: J Ma; E Giovannucci; M Pollak; J M Chan; J M Gaziano; W Willett; M J Stampfer Journal: J Natl Cancer Inst Date: 2001-09-05 Impact factor: 13.506
Authors: Pamela A Hershberger; Terence F McGuire; Wei-Dong Yu; Eleanor G Zuhowski; Jan H M Schellens; Merrill J Egorin; Donald L Trump; Candace S Johnson Journal: Mol Cancer Ther Date: 2002-08 Impact factor: 6.261
Authors: Shanna Nesby-O'Dell; Kelley S Scanlon; Mary E Cogswell; Cathleen Gillespie; Bruce W Hollis; Anne C Looker; Chris Allen; Cindy Doughertly; Elaine W Gunter; Barbara A Bowman Journal: Am J Clin Nutr Date: 2002-07 Impact factor: 7.045
Authors: K Ng; B M Wolpin; J A Meyerhardt; K Wu; A T Chan; B W Hollis; E L Giovannucci; M J Stampfer; W C Willett; C S Fuchs Journal: Br J Cancer Date: 2009-08-18 Impact factor: 7.640
Authors: Kathleen M Wesa; Neil H Segal; Angel M Cronin; Daniel D Sjoberg; Gria N Jacobs; Marci I Coleton; Martin Fleisher; Ann M Dnistrian; Leonard B Saltz; Barrie R Cassileth Journal: Nutr Cancer Date: 2015-02-03 Impact factor: 2.900
Authors: Chen Yuan; Lindsay Renfro; Pratibha B Ambadwar; Fang-Shu Ou; Howard L McLeod; Federico Innocenti; Jeffrey A Meyerhardt; Brian M Wolpin; Richard M Goldberg; Axel Grothey; Charles S Fuchs; Kimmie Ng Journal: Cancer Causes Control Date: 2019-05-18 Impact factor: 2.506
Authors: Elizabeth Loehrer; Rebecca A Betensky; Edward Giovannucci; Li Su; Andrea Shafer; Bruce W Hollis; David C Christiani Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-06-11 Impact factor: 4.254
Authors: Jeffrey A Meyerhardt; Kimmie Ng; Chen Yuan; Kaori Sato; Bruce W Hollis; Sui Zhang; Donna Niedzwiecki; Fang-Shu Ou; I-Wen Chang; Bert H O'Neil; Federico Innocenti; Heinz-Josef Lenz; Charles D Blanke; Richard M Goldberg; Alan P Venook; Robert J Mayer; Charles S Fuchs Journal: Clin Cancer Res Date: 2019-09-23 Impact factor: 12.531
Authors: Katherine Van Loon; Kouros Owzar; Chen Jiang; Hedy L Kindler; Mary F Mulcahy; Donna Niedzwiecki; Eileen M O'Reilly; Charles Fuchs; Federico Innocenti; Alan P Venook Journal: J Natl Cancer Inst Date: 2014-08-06 Impact factor: 13.506